Consider a short position in Capricor Therapeutics (CAPR), as negative data expected in approximately two weeks could lead to a 50% downside. Another high-conviction short is the quantum computing sector, specifically targeting D-Wave (QBTS), due to concerns about extreme overvaluation. For a high-risk, high-reward long position, look at Summit Therapeutics (SMMT), as the market may be undervaluing its promising drug data. A more conventional long idea is Sarepta (SRPT), with a potential price target of $50. Lastly, investors should avoid Organon (OGN) due to major red flags from a recent accounting scandal and CEO departure.

Summit Therapeutics (SMMT)

• The speaker was initially inclined to short the stock, calling it "quite risky" as its high valuation is based on the hopes of a single drug, Ivonescamab.
• After reviewing the data from a head-to-head trial against a PD-1 inhibitor, he described it as "fucking good data". He questions if the market is discounting the stock because the data is from China.
• He notes that the company has powerful backers, including the Baker Brothers (who own almost $1 billion worth), but that traditional hedge funds seem to be avoiding it.
• There is not a significant short interest in the stock, suggesting that even the bears are not confident enough to bet against it.
• The speaker believes that if the drug is successful and beats Pembro (Keytruda), Summit could become a $100 billion or $200 billion company on its own.
• The company recently raised $526.7 million, addressing near-term cash concerns.

Takeaways

• Contrarian Bullish Opportunity: The speaker's sentiment shifts from bearish to bullish during the analysis. He sees a potential opportunity because hedge funds seem scared to invest but are also unwilling to short it.
• High-Risk, High-Reward: This is a speculative biotech play entirely dependent on the success of one drug. A positive outcome could lead to massive returns, but a failure would be catastrophic for the stock.
• Key Thesis: The investment thesis is that the market is overly skeptical of the Chinese data for Ivonescamab. If the data proves to be legitimate and the drug is successful, the stock is significantly undervalued.

Quantum Computing (Theme)

• The speaker is extremely bearish on the quantum computing sector, stating "I am still mega short, Quantum."
• He specifically mentions being short D-Wave (QBTS) and expresses frustration at the recent rally in quantum stocks like D-Wave and IonQ (IONQ), calling their upward moves "annoying" and "chagrin."
• He criticizes a venture capitalist guest for being bullish on the sector regardless of price, suggesting that VCs are not price-sensitive and that the public market valuations are illogical.
• He dismisses the idea of "quantum on the battlefield" as nonsensical, reinforcing his view that the hype is disconnected from reality.

Takeaways

• Strong Bearish Stance: The speaker has a high-conviction short position against the quantum computing sector. This is a strong contrarian view against a sector with powerful upward momentum.
• Specific Short: He has explicitly identified a short position in D-Wave (QBTS).
• Valuation Concerns: The core of the bearish thesis is that public company valuations in the quantum space are detached from fundamental reality and are not a sensible investment at current prices. Investors should be extremely cautious of the hype in this sector.

Capricor Therapeutics (CAPR)

• The speaker is very bearish on Capricor, stating "it's a good short".
• He believes the company's drug "doesn't do anything".
• He mentions that the company has data coming out in approximately two weeks, which he expects to be negative.
• He sees a potential downside of ~50%, suggesting the stock could fall from its current price to around $2.14 (based on his numbers of $2.69 cash per share and a target of $2.14).

Takeaways

• Actionable Short Idea: This is presented as a short-term short trade based on an upcoming binary event (data release).
• High-Risk Catalyst: The trade's success hinges on the data release being negative, as the speaker predicts. A positive surprise could cause the stock to rally sharply, leading to significant losses for anyone short.

Biotech Long Positions

The speaker mentioned three specific biotech stocks he is currently long.

• Sarepta (SRPT):
  • He is long Sarepta and mentions that "Link still likes Sarepta."
  • He provides a specific price target, stating "I think Surreptic can go to 50." (Contextually referring to Sarepta).
• Spruce Biosciences (SPRB):
  • He is "still on SPRB" and refers to it as "The Spruce Moose."
  • He notes that a "big chunk of Wall Street bought that" and that it has "some good investors."
• Abivax (ABVX):
  • He states simply, "I'm long Abivax."
  • He also mentions "Anivex" (likely a typo for Abivax) as one of the "big ones" with an upcoming binary event.

Takeaways

• Bullish Conviction: The speaker has allocated capital to these three biotech companies, indicating a bullish outlook on their prospects.
• Sarepta Price Target: Investors bullish on Sarepta may find the $50 price target an interesting data point for their own analysis.
• Institutional Interest in Spruce: The mention of "good investors" and "Wall Street" buying SPRB suggests strong institutional backing, which can be a positive signal.

Biotech Shorts & Cautions

• SELLAS Life Sciences (SLS):
  • The speaker calls SLS "a short" multiple times.
  • He identifies it as having one of the "biggest binary" events pending, but the timing of the data release is unknown and "very opaque," making it a difficult short to time.
• Organon (OGN):
  • The stock is down 20% on news that the CEO is gone following an investigation.
  • The speaker highlights the reason as "Channel stuffing," an accounting scandal where a company inflates its sales figures by forcing more products into its distribution channel than can be sold. He calls this "crazy."
  • Takeaway: This is a stock to avoid. The combination of a CEO departure and an accounting scandal is a major red flag.
• Arc-T (ARCT):
  • The speaker notes that the company's cystic fibrosis drug failed.
  • He believes this was the company's "big hope," and now "that hope is gone."
  • Takeaway: A key part of the company's pipeline has failed, which is a significant bearish development.
• Joby (JOBY):
  • He describes Joby as "kind of a scam I think."
  • Takeaway: A strong, negative opinion on the company's legitimacy.

Other Market Mentions

• Argentinian Stocks:
  • The speaker notes that Argentinian stocks and the peso are surging following the election of Javier Milei. The main stock index jumped 20%.
  • Takeaway: This is a politically-driven momentum trade. Investors could look into Argentinian ADRs or ETFs to gain exposure to this trend, but should be aware of the high volatility associated with emerging markets and political events.
• Beyond Meat (BYND):
  • He calls his investment in Beyond Meat a "nice win" but says he "covered way too early."
  • Takeaway: He remains bullish on the company and regrets selling his position, suggesting he believes there is still upside.
• NVIDIA (NVDA):
  • He mentions NVIDIA is up 2% to $190 amid "a lot of AI chatter."
  • Takeaway: This is an observation of continued bullish momentum in a leading AI stock.
• Palantir (PLTR):
  • He notes that Palantir is at an "all-time high" and has "barely had a drawdown."
  • Takeaway: Another observation of strong, persistent bullish momentum in a popular stock.
• GameStop (GME):
  • He is completely dismissive, asking "Who cares about GameStop? Who gives a shit?"
  • Takeaway: He sees no investment value here.